|Bid||22.63 x 800|
|Ask||22.69 x 800|
|Day's Range||22.50 - 22.76|
|52 Week Range||12.20 - 31.18|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||29.10|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy. 2/31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of 6%, while 15 patients achieved stable disease for at least 12 weeks. The combination w
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.